Therapy Name | Atezolizumab + Talimogene laherparepvec |
Therapy Description |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Atezolizumab | Tecentriq | RG7446|MPDL3280A | Immune Checkpoint Inhibitor 99 PD-L1/PD-1 antibody 48 | Tecentriq (atezolizumab) is a monoclonal antibody that binds to PD-L1 (CD274), preventing activation of its receptor, potentially enhancing T-cell-mediated immune response to neoplasms and inhibiting T-cell inactivation (PMID: 29449897). Tecentriq (atezolizumab) is FDA approved for use in patients with PD-L1-expressing advanced urothelial carcinoma ineligible for cisplatin-containing chemotherapy, advanced urothelial carcinoma ineligible for or progressed on platinum-containing therapy regardless of PD-L1 expression, metastatic non-small cell lung cancer (NSCLC) progressed on platinum-containing therapy, and in combination with bevacizumab, paclitaxel, and carboplatin for non-squamous NSCLC with no EGFR or ALK aberrations (FDA.gov). |
talimogene laherparepvec | Imlygic | OncoVEX GM-CSF | Imlygic (talimogene laherparepvec) is a GM-CSF expressing herpes simplex type-1 virus (HSV-1) that selectively infects and lyses tumor cells, and potentially induces a cytotoxic immune response against tumor cells (PMID: 25777572). Imlygic (talimogene laherparepvec) is FDA approved for use in patients with recurrent melanoma (FDA.gov). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status |
---|---|---|---|---|
NCT03256344 | Phase I | Atezolizumab + Talimogene laherparepvec | A Safety Study of Talimogene Laherparepvec Combined With Atezolizumab for Triple Negative Breast Cancer and Colorectal Cancer With Liver Metastases | Recruiting |